Gene Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT04866017	Phase III	Durvalumab BGBA1217 + Tislelizumab Tislelizumab	A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer	Terminated	USA \| ESP \| AUS	2
NCT03175224	Phase Ib/II	Vebreltinib	APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)	Recruiting	USA \| ITA \| HUN \| GBR \| FRA \| FIN \| ESP \| CAN \| AUS	4
NCT01829217	Phase II	Sunitinib	Sunitinib in Never-Smokers With Lung Adenocarcinoma	Completed	USA	0
NCT03037385	Phase Ib/II	Pralsetinib	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL	5
NCT05313009	Phase Ib/II	Sotorasib + TH-4000	Tarlox and Sotorasib in Patients With KRAS G12C Mutations	Terminated	USA	0
NCT04211337	Phase III	Vandetanib Cabozantinib Selpercatinib	A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)	Active, not recruiting	USA \| POL \| NLD \| ITA \| ISR \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUS	5
NCT06031688	Phase II	Tepotinib Ramucirumab + Tepotinib	Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)	Recruiting	USA	0
NCT01877811	Phase Ib/II	RXDX-105	CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2	Completed	USA	0
NCT04984811	Phase II	Atezolizumab + NT-I7	NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC	Active, not recruiting	USA	0
NCT05401786	Phase II	Cemiplimab Ipilimumab	Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC (RAD-IO)	Recruiting	NLD	0
NCT05241873	Phase Ib/II	BLU-451	(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations	Active, not recruiting	USA \| CAN	3
NCT06094296	Phase II	Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel	A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	Completed	USA \| AUS	0
NCT06007924	Phase II	Defactinib + RO5126766	A Study of Avutometinib and Defactinib in People With Thyroid Cancer	Recruiting	USA	0
NCT05240131	Phase Ib/II	Atezolizumab + GB1211	A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).	Active, not recruiting	POL \| FRA \| ESP	0
NCT05788926	Phase I	TG6050	A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)	Recruiting	FRA	0
NCT05117242	Phase II	GEN1046 + Pembrolizumab GEN1046	Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer	Active, not recruiting	USA \| POL \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU	1
NCT04131543	Phase II	Cabozantinib	Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA)	Unknown status	ITA	0
NCT05255302	Phase II	Pembrolizumab + Pemetrexed Disodium Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab	De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction (DIAL)	Recruiting	FRA	0
NCT02193152	Phase I	Pazopanib	Pazopanib in Molecularly Selected Patients With Advanced NSCLC	Terminated	USA	0
NCT06680050	Phase II	Ceralasertib + Durvalumab	Phase II Study of Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen (AUSTRAL) (AUSTRAL)	Not yet recruiting	ITA \| CHE	0
NCT03194893	Phase III	Crizotinib Alectinib	A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer	Recruiting	USA \| TUR \| POL \| ITA \| FRA \| ESP	4
NCT05555732	Phase III	Datopotamab deruxtecan + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Datopotamab deruxtecan + Pembrolizumab Cisplatin + Datopotamab deruxtecan + Pembrolizumab	Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)	Recruiting	USA \| TUR \| ROU \| POL \| NLD \| ITA \| HUN \| GRC \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	8
NCT02867592	Phase II	Cabozantinib	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors	Active, not recruiting	USA	0
NCT02299141	Phase I	Nintedanib	Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer	Active, not recruiting	USA	0
NCT05815173	Phase I	Ladarixin + Sotorasib	Ladarixin With Sotorasib in Advanced NSCLC	Recruiting	USA	0
NCT06074588	Phase III	Docetaxel SKB264 Pemetrexed Disodium	Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)	Recruiting	USA \| TUR \| POL \| ITA \| ISR \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| AUS	10
NCT05777603	Phase I	Aztreonam + Pembrolizumab + Vancomycin	Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer	Recruiting	USA	0
NCT05815186	Phase II	Ladarixin + Sotorasib	Ladarixin With Sotorasib in Advanced NSCLC - Phase II	Withdrawn	USA	0
NCT05215340	Phase III	Pembrolizumab Datopotamab deruxtecan + Pembrolizumab	Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)	Recruiting	USA \| TUR \| ROU \| POL \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	9
NCT06119581	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Cisplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium LY3537982 + Pembrolizumab Carboplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium	A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01)	Recruiting	USA \| TUR \| SWE \| ROU \| POL \| NOR \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS	7
NCT01877083	Phase II	Lenvatinib	Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung	Completed	USA	4
NCT05064280	Phase II	Lenvatinib Pembrolizumab	Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases	Recruiting	USA	0
NCT03468985	Phase II	Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Nivolumab	Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer	Completed	USA	0
NCT03178552	Phase II	Entrectinib Carboplatin + Cisplatin + Gemcitabine Atezolizumab Carboplatin + Cisplatin + Pemetrexed Disodium Divarasib Atezolizumab + Cobimetinib + Vemurafenib Alectinib	A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST)	Active, not recruiting	USA \| TUR \| POL \| NZL \| ITA \| ISR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS \| ARG	14
NCT03255083	Phase I	DS-1205c + Osimertinib	DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer	Terminated		1
NCT05153408	Phase Ib/II	BLU-701 BLU-701 + Osimertinib BLU-701 + Carboplatin + Pemetrexed Disodium	(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC	Terminated	USA	0
NCT05589818	Phase II	Pembrolizumab	Pembrolizumab for Advanced NSCLC and PS 2-3	Recruiting	USA	0
NCT05541822	Phase II	ABN401	To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation	Recruiting	USA	2
NCT05469178	Phase Ib/II	Bemcentinib + Carboplatin + Pembrolizumab + Pemetrexed Disodium	A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer	Recruiting	USA	0
NCT06635824	Phase III	Docetaxel GEN1046 + Pembrolizumab	Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)	Recruiting	USA	0
NCT01831726	Phase II	Dovitinib	Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	Completed	USA	0
NCT06120075	Phase I	AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab	A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27)	Recruiting	USA	0
NCT05048797	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Trastuzumab deruxtecan	A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations	Recruiting	USA \| TUR \| POL \| NLD \| ITA \| FRA \| ESP \| DNK \| DEU \| CAN \| BRA \| BEL \| AUT	7
NCT03131206	Phase Ib/II	Alectinib	A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer	Terminated	USA	0
NCT01813734	Phase II	Ponatinib	Ponatinib in Advanced NSCLC w/ RET Translocations	Completed	USA	0
NCT05443126	Phase Ib/II	EP0031	A Study of EP0031 in Patients With Advanced RET-altered Malignancies	Recruiting	USA \| GBR \| FRA \| ESP	1
NCT05502237	Phase III	AB154 + Cisplatin + Pemetrexed Disodium AB154 + Carboplatin + Paclitaxel Cisplatin + Pembrolizumab + Pemetrexed Disodium AB154 + Carboplatin + Nab-paclitaxel AB154 + Carboplatin + Pemetrexed Disodium + Zimberelimab Carboplatin + Pembrolizumab + Pemetrexed Disodium AB154 + Carboplatin + Paclitaxel + Zimberelimab AB154 + Carboplatin + Nab-paclitaxel + Zimberelimab AB154 + Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab AB154 + Cisplatin + Pemetrexed Disodium + Zimberelimab	Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121)	Active, not recruiting	USA \| TUR \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUT \| ARG	9
NCT01396408	Phase II	Temsirolimus Sunitinib	A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours	Active, not recruiting	CAN	0
NCT01896479	FDA approved	Cabozantinib	A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER)	Active, not recruiting	SWE \| ROU \| POL \| NLD \| ITA \| ISR \| HUN \| HRV \| FRA \| ESP \| CAN \| AUS	2
NCT04105270	Phase II	Carboplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium	RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial	Recruiting	USA	0
NCT04683250	Phase Ib/II	Vepafestinib	Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities ((MARGARET))	Recruiting	USA	1
NCT03052569	Expanded access	RXDX-105	Expanded Access to RXDX-105 for Cancers With RET Alterations	No longer available	USA	0
NCT04760288	Phase III	Cabozantinib Pralsetinib Vandetanib	A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). (AcceleRET-MTC)	Withdrawn	ESP	0
NCT02693535	Phase II	Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)	Recruiting	USA	0
NCT05565417	Phase Ib/II	IMT-009	Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas	Recruiting	USA	0
NCT03639714	Phase Ib/II	GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab	A Study of a Personalized Neoantigen Cancer Vaccine	Completed	USA \| AUS	0
NCT03780517	Phase I	DS-5010	Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors	Completed	USA \| FRA \| ESP \| BEL	3
NCT03157128	Phase Ib/II	Selpercatinib	A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001)	Active, not recruiting	USA \| ITA \| ISR \| GBR \| FRA \| ESP \| DNK \| DEU \| CHE \| CAN \| AUS	5
NCT03934372	Phase Ib/II	Ponatinib	Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors	Recruiting	SWE \| NLD \| ITA \| GBR \| FRA \| ESP \| DNK \| DEU \| BEL	0
NCT03391869	Phase III	Ipilimumab + Nivolumab	Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT06067776	Phase I	Cetuximab + Osimertinib + Tucatinib	Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer	Not yet recruiting	USA	0
NCT04268550	Phase II	Selpercatinib	Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)	Active, not recruiting	USA	0
NCT05781308	Phase II	Atezolizumab + Bevacizumab + Paclitaxel Bevacizumab + Paclitaxel	Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy (ADAPTABLE)	Active, not recruiting	FRA	0
NCT04940052	Phase III	Dabrafenib + Trametinib	Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer	Active, not recruiting	USA \| TUR \| CAN \| BRA \| ARG	6
NCT05668962	Phase II	Selpercatinib	Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC	Recruiting	USA	0
NCT04222972	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Pralsetinib Cisplatin + Gemcitabine Carboplatin + Gemcitabine Cisplatin + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium	A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)	Active, not recruiting	USA \| TUR \| SWE \| POL \| NOR \| NLD \| ITA \| IRL \| GBR \| FRA \| ESP \| DEU \| CHE \| BRA \| BEL \| AUS \| ARG	6
NCT05845671	Phase Ib/II	Amivantamab-vmjw	Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations	Recruiting	USA	0
NCT04194944	Phase III	Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Selpercatinib Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium	A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)	Active, not recruiting	TUR \| ROU \| POL \| NLD \| ITA \| ISR \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUS \| ARG	9
NCT06364917	Phase II	Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab	DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC	Not yet recruiting	USA	0
NCT06625775	Phase I	BBO-10203 + Trastuzumab BBO-10203	Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101)	Recruiting	USA	0
NCT03755102	Phase I	Dacomitinib	A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.	Completed	USA	0
NCT04862780	Phase Ib/II	BLU-945 BLU-945 + Osimertinib	(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	Active, not recruiting	USA \| NLD \| GBR \| FRA \| ESP \| CAN	4
NCT06495125	Phase II	Defactinib + Nivolumab + RO5126766	Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT05364645	Phase II	Carboplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium + Selpercatinib	Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer	Withdrawn	USA	0
NCT04581824	Phase II	Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Dostarlimab-gxly + Pemetrexed Disodium Carboplatin + Dostarlimab-gxly + Pemetrexed Disodium	Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)	Active, not recruiting	USA \| ROU \| POL \| ITA \| FRA \| ESP \| DEU \| BRA \| ARG	3
NCT03784378	Phase I	RXDX-105	Continued Access to RXDX-105	Completed	USA	0
NCT06275360	Phase II	Nivolumab Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel	Repositioning Immunotherapy in VetArans With Lung Cancer (RIVAL)	Recruiting	USA	0
NCT04320888	Phase II	Selpercatinib	Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial	Active, not recruiting	USA \| AUS	1
NCT05935774	Phase II	Atezolizumab + Trabedersen	OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer	Withdrawn	USA	0
NCT04161391	Phase Ib/II	TPX-0046	Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations	Terminated	USA	1
NCT04892953	Phase II	Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Nab-paclitaxel Carboplatin + Durvalumab + Gemcitabine Durvalumab	Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy	Recruiting	USA	0
NCT04302025	Phase II	Cobimetinib + Vemurafenib Entrectinib Atezolizumab Alectinib Pralsetinib	A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT05570825	Phase II	Pembrolizumab + SX-682	SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT04551521	Phase II	Atezolizumab Atezolizumab + Ipatasertib Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Cobimetinib Alectinib Atezolizumab + Cobimetinib + Vemurafenib	CRAFT: The NCT-PMO-1602 Phase II Trial	Recruiting	DEU	0
NCT05170204	Phase III	Durvalumab Alectinib Pralsetinib Entrectinib	A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)	Recruiting	USA \| TUR \| SWE \| POL \| NZL \| NOR \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS	11
NCT04736173	Phase III	Zimberelimab Carboplatin + Paclitaxel + Pemetrexed Disodium AB154 + Zimberelimab Pembrolizumab	Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10)	Active, not recruiting	USA \| TUR \| GRC	9
NCT05715229	Phase II	Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Ipilimumab + Nivolumab	Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy (G360-IIT)	Recruiting	USA	0
NCT01639508	Phase II	Cabozantinib	Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity	Recruiting	USA	0
NCT05200481	Phase II	Brigatinib + Carboplatin + Pemetrexed Disodium Brigatinib	Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)	Active, not recruiting	FRA	0
NCT02587650	Phase II	Ceritinib Capmatinib Regorafenib Entrectinib	Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma	Terminated	USA	0
NCT06532032	Phase Ib/II	Amivantamab-vmjw + Docetaxel	A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer (swalloWTail)	Recruiting	USA \| TUR	1
NCT05671510	Phase III	ONC-392 Docetaxel	ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)	Recruiting	USA \| TUR \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	2
NCT02314481	Phase II	Vemurafenib Atezolizumab Alectinib Ado-trastuzumab emtansine	Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWINII)	Active, not recruiting	GBR	0
NCT02925234	Phase II	Crizotinib Sunitinib Niraparib Olaparib Lorlatinib Erdafitinib Talazoparib Dacomitinib Axitinib Panitumumab	The Drug Rediscovery Protocol (DRUP Trial) (DRUP)	Recruiting	NLD	0
NCT04759911	Phase II	Selpercatinib	Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer	Active, not recruiting	USA	0
NCT04819100	Phase III	Selpercatinib	A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)	Recruiting	USA \| TUR \| SWE \| ROU \| POL \| NOR \| NLD \| ITA \| ISR \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA \| BEL \| AUT \| AUS	11
NCT04484142	Phase II	Datopotamab deruxtecan	Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)	Active, not recruiting	USA \| NLD \| ITA \| HUN \| FRA \| ESP \| DEU	3
NCT05435846	Phase I	Capmatinib + Trametinib	Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation	Terminated	USA	0
NCT05676749	Phase I	Aldesleukin + C-TIL051 + Pembrolizumab	C-TIL051 in Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT03334617	Phase II	Danvatirsen + Durvalumab Durvalumab + Olaparib Cediranib + Durvalumab Durvalumab + Vistusertib Durvalumab + Trastuzumab deruxtecan Ceralasertib + Durvalumab	Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)	Active, not recruiting	USA \| ISR \| FRA \| ESP \| DEU \| CAN \| AUT	1
NCT04526691	Phase I	Cisplatin + Datopotamab deruxtecan + Pembrolizumab Carboplatin + Datopotamab deruxtecan + Pembrolizumab Datopotamab deruxtecan + Pembrolizumab	Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)	Active, not recruiting	USA \| ITA \| ESP	2
NCT03155620	Phase II	Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Recruiting	USA \| CAN \| AUS	1
NCT02949843	Phase II	Nivolumab + Pembrolizumab	Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations	Terminated	USA	0
NCT05159245	Phase II	Vemurafenib Tepotinib Vismodegib Apalutamide Alectinib Regorafenib Entrectinib Pertuzumab + Trastuzumab Pemigatinib Atezolizumab Cobimetinib Dabrafenib + Trametinib Dabrafenib Trametinib Abemaciclib	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE)	Recruiting	FIN	0
NCT04116541	Phase II	Alectinib Cabozantinib Ribociclib + Siremadlin	A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST)	Recruiting	FRA	0
NCT05241834	Phase I	LOXO-260	A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment	Active, not recruiting	USA	0
NCT03899792	Phase Ib/II	Selpercatinib	A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors (LIBRETTO-121)	Recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| AUS	2
NCT03953235	Phase Ib/II	GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab	A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens	Completed	USA	0
NCT02272998	Phase II	Ponatinib	Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.	Active, not recruiting	USA	0
NCT05687266	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Datopotamab deruxtecan + Durvalumab Cisplatin + Pembrolizumab + Pemetrexed Disodium	Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)	Recruiting	USA \| TUR \| SWE \| POL \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BRA \| BGR \| AUT	8
NCT03906331	Expanded access	Selpercatinib	Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation	Available	USA \| POL \| NZL \| ITA \| ISR \| FRA \| ESP \| DEU \| CHE \| AUS	3
NCT04631744	Phase II	Cabozantinib	Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)	Recruiting	USA	0
NCT06561386	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nivolumab + Pemetrexed Disodium + Relatlimab	A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49% (RELATIVITY1093)	Recruiting	USA \| ROU \| POL \| NLD \| ITA \| IRL \| GBR \| FRA \| ESP \| DNK \| DEU \| CHE \| BRA \| BEL \| AUT \| AUS \| ARG	7
NCT01935336	Phase II	Ponatinib	Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers	Completed	USA	0

Gene Detail

Contact

Filtering

Sorting